Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT07127978 · ClinicalTrials.gov registry record
A Study Evaluating the Real-World Experience of Givinostat in Patients With Duchenne Muscular Dystrophy
A clinical trial of Duchene Muscular Dystrophy, sponsored by ITF Therapeutics.
- Recruiting
- Registry status
- 300
- Enrollment target
- 2
- Study locations
NCT07127978 is a study of Duchene Muscular Dystrophy that is actively recruiting participants, run by ITF Therapeutics. The registered enrollment target is 300 participants. The trial reports 2 study locations across 2 states.
The verdict
NCT07127978, a study of Duchene Muscular Dystrophy, is actively recruiting participants, sponsored by ITF Therapeutics.
- RECRUITING
- Registry status
- 300 participants
- Enrollment target
- 2
- Study locations
Study Summary
This is a prospective observational study conducted to evaluate safety, tolerability, and functional outcomes of patients with DMD newly initiating oral givinostat or having started therapy within 6 months as part of routine clinical care in the US. The study has a planned maximum duration of 5 years for the first enrolled patients, including a 24-month enrollment period and a minimum of 2 years of follow-up.
Conditions Studied
Study Locations (2)
Illinois
- Ann and Robert H. Lurie Children's Hospital of Chicago - Chicago
Massachusetts
- University of Massachusetts Chan Medical School - Worcester
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 300 participants |
| Start Date | 2025-10-23 |
| Est. Completion | 2030-07-30 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT07127978
The ClinicalTrials.gov registry entry for NCT07127978 describes a study currently listed as recruiting, categorized as an unspecified phase. The registered enrollment target is 300 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is ITF Therapeutics, which has 1 total studies on file at ClinicalTrials.gov.
The record links to 1 condition, with Duchene Muscular Dystrophy appearing as the primary indexed condition, and to 0 interventions.
NCT07127978 reports 2 study locations spanning 2 distinct geographic areas - top geographies include Illinois, Massachusetts.
Frequently Asked Questions
What is clinical trial NCT07127978 about?
NCT07127978 is a clinical study titled "A Study Evaluating the Real-World Experience of Givinostat in Patients With Duchenne Muscular Dystrophy". This is a prospective observational study conducted to evaluate safety, tolerability, and functional outcomes of patients with DMD newly initiating oral givinostat or having started therapy within 6 months as part of routine clinical care in the US. The study has a planned maximum duration of 5 year...
What is the current status of trial NCT07127978?
This trial is currently recruiting. The enrollment target is 300 participants. The study started on 2025-10-23. Estimated completion is 2030-07-30.
What conditions does trial NCT07127978 study?
This clinical trial studies the following conditions: Duchene Muscular Dystrophy.
Who is sponsoring clinical trial NCT07127978?
This trial is sponsored by ITF Therapeutics, which has 1 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT07127978 being conducted?
This trial has 2 study locations across Illinois, Massachusetts. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.